doravirine + lamivudine

Doravirine + lamivudine is a two-drug antiretroviral combination used in the treatment of human immunodeficiency virus type 1 (HIV-1) infection. Doravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI), while lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI). Both drugs act by inhibiting the HIV-1 reverse transcriptase enzyme, but at different binding sites and through distinct mechanisms. This combination reduces viral replication and lowers HIV levels in the body, helping to preserve immune function and delay progression to acquired immunodeficiency syndrome (AIDS). While fixed-dose combinations containing both agents exist with additional drugs such as tenofovir disoproxil fumarate, there is no widely marketed or approved two-drug product consisting solely of doravirine and lamivudine as of May 2025. The primary indication for this combination would be HIV-1 infection in adults or children who require antiretroviral therapy.